Prognostic Significance of Primary Tumor Location in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Retrospective, Multi-Center Cohort Study in Taiwan

We sought to examine the effect of tumor location on the prognosis of patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). This retrospective study came from the Taiwan UTUC Collaboration Group, which consisted of 2658 patients at 15 institutions in Taiwan from 1988 to 2019. Patients with kidney-sparing management, both renal pelvic and ureteral tumors, as well as patients lacking complete data were excluded; the remaining 1436 patients were divided into two groups: renal pelvic tumor (RPT) and ureteral tumor (UT), with 842 and 594 patients, respectively. RPT was associated with more aggressive pathological features, including higher pathological T stage (p < 0.001) and the presence of lymphovascular invasion (p = 0.002), whereas patients with UT often had synchronous bladder tumor (p < 0.001), and were more likely to bear multiple lesions (p = 0.001). Our multivariate analysis revealed that UT was a worse prognostic factor compared with RPT (overall survival: HR 1.408, 95% CI 1.121–1.767, p = 0.003; cancer-specific survival: HR 1.562, 95% CI 1.169–2.085, p = 0.003; disease-free survival: HR 1.363, 95% CI 1.095–1.697, p = 0.006; bladder-recurrence-free survival: HR 1.411, 95% CI 1.141–1.747, p = 0.002, respectively). Based on our findings, UT appeared to be more malignant and had a worse prognosis than RPT.

[1]  A. Masson-Lecomte,et al.  European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. , 2020, European urology.

[2]  S. Boorjian,et al.  Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  K. Bensalah,et al.  PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. , 2019, Urologic oncology.

[4]  B. Taylor,et al.  Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma , 2018, Clinical Cancer Research.

[5]  N. Xu,et al.  Risk factors for bladder cancer recurrence survival in patients with upper-tract urothelial carcinoma , 2018, Tumori.

[6]  Y. Osman,et al.  Muscle-invasive bladder and urethral cancer recurrence after surgical management of upper tract urothelial carcinoma: A review of 305 patients. , 2018, Turkish journal of urology.

[7]  T. Powles,et al.  First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. , 2017, The Lancet. Oncology.

[8]  Chang-li Wu,et al.  Prognostic significance of urothelial carcinoma with divergent differentiation in upper urinary tract after radical nephroureterectomy without metastatic diseases , 2017, Medicine.

[9]  Choung-Soo Kim,et al.  Impact of Tumor Location on Local Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma: Implications for Adjuvant Radiotherapy , 2017, Clinical genitourinary cancer.

[10]  M. Babjuk,et al.  Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC) , 2017, World Journal of Urology.

[11]  Sheau-Fang Yang,et al.  Prognostic Significance of Lymphovascular Invasion in Upper Urinary Tract Urothelial Carcinoma is Influenced by Tumor Location , 2015, Annals of Surgical Oncology.

[12]  B. Milojevic,et al.  Urothelial carcinoma: Recurrence and risk factors. , 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[13]  Chao-yuan Huang,et al.  Diabetes mellitus with poor glycemic control increases bladder cancer recurrence risk in patients with upper urinary tract urothelial carcinoma , 2015, Diabetes/metabolism research and reviews.

[14]  Jonathan Izawa,et al.  Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration. , 2014, Urologic oncology.

[15]  C. Tulić,et al.  Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma. , 2013, Urologic oncology.

[16]  Tianyuan Xu,et al.  Ureteral tumours showing a worse prognosis than renal pelvis tumours may be attributed to ureteral tumours more likely to have hydronephrosis and less likely to have haematuria , 2013, World Journal of Urology.

[17]  S. Shariat,et al.  Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy , 2012, BJU international.

[18]  F. Saint,et al.  Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. , 2011, European urology.

[19]  J. Coleman,et al.  The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. , 2010, European urology.

[20]  S. Shariat,et al.  Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. , 2010, European urology.

[21]  K. Bensalah,et al.  Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. , 2010, European urology.

[22]  F. Montorsi,et al.  Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. , 2009, The Journal of urology.

[23]  Y. Lotan,et al.  Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration , 2009, Cancer.

[24]  K. Bensalah,et al.  Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Rehak,et al.  Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location , 2006, BJU international.

[26]  H. Ozen,et al.  Prognostic significance of bladder tumor history and tumor location in upper tract transitional cell carcinoma. , 2006, The Journal of urology.

[27]  Liang Cheng,et al.  Molecular Evidence Supporting Field Effect in Urothelial Carcinogenesis , 2005, Clinical Cancer Research.

[28]  R. Takahashi,et al.  Metachronous multifocal development of urothelial cancers by intraluminal seeding , 1993, The Lancet.

[29]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[30]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[31]  H. Miyake,et al.  Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract. , 2008, Urology.

[32]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.